Introduction {#s1}
============

*In vitro* fertilization (IVF) is a complex, multistep process. Oocytes-containing follicles are collected after controlled ovarian hyperstimulation (COH) with follicle stimulating hormone (FSH). Some of the subsequently fertilized oocytes will be transferred to the uterus for implantation, whereas others may be cryopreserved for future implantation attempts (or destroyed if they are unlikely to survive cryopreservation). All these steps are critical for successful IVF.

The aim of COH is to safely obtain a high number of mature oocytes so that the most viable embryo can be selected for transfer. Both quantitative and qualitative factors in oocyte production have a high influence on the IVF outcome. The goal is to transfer a single embryo and thus reduce the risk of multiple pregnancies - the main complication of IVF [@pone.0038700-Grady1].

The significant inter-individual variability to COH with FSH is one of the most challenging issues in IVF treatment. Although low responses are troublesome, high responses can trigger a serious medical condition - ovarian hyperstimulation syndrome (OHSS). Hence, the ability to predict an individual's responses to COH would constitute a major advance in patient care. Although many hormonal and clinical parameters (such as baseline FSH [@pone.0038700-Scott1], oestradiol [@pone.0038700-Licciardi1], inhibin B [@pone.0038700-Hofmann1] and anti-Mullerian hormone (AMH) levels [@pone.0038700-Ficicioglu1], patient age [@pone.0038700-Schwartz1] and the antral follicle count [@pone.0038700-Hendriks1]) have been used to optimize COH, none of these markers have significant predictive value when considered alone [@pone.0038700-Scott2], [@pone.0038700-Ocal1], However, predictive performance levels can be improved by considering combinations of these parameters [@pone.0038700-Srouji1].

Despite these advances in patient management, there is still a need to individualise and optimise stimulation protocols, reduce the likelihood of an extreme response and thus increase the probability of a live birth. A complementary strategy involves studying the pharmacogenetics of the COH response. Candidate genes should have a specific effect on the reproductive system and present single-nucleotide polymorphisms (SNPs) that affect gene expression or function.

10.1371/journal.pone.0038700.t001

###### Allele frequencies of the studied SNPs in our population and in the NCBI database.

![](pone.0038700.t001){#pone-0038700-t001-1}

  Candidate SNP    Allele frequencies                                             
  --------------- -------------------- --------------------- -------------------- --------
  AMH                     A/C           654 (76%)/206 (24%)   159 (71%)/65 (29%)   82%18%
  AMHR                     AG           700 (82%)156 (18%)    176 (79%)48 (21%)    83%17%
  BMP15                    CG           193 (23%)663 (77%)    65 (29%)159 (71%)    23%77%
  ESR1                     AG           428 (52%)398 (48%)    112 (50%)112 (50%)   58%42%
  ESR2                     GA           520 (61%)336 (39%)    136 (61%)88 (39%)    62%38%
  FSHR                     AG           475 (56%)379 (44%)    136 (61%)88 (39%)    60%40%
  HLA-G                    CG            765 (90%)89 (10%)    197 (88%)27 (12%)    84%16%
  MTHFR1                   TC           216 (28%)563 (72%)    81 (36%)141 (63%)    31%69%
  MTHFR2                   AC           623 (73%)227 (27%)    160 (73%)60 (27%)    70%30%
  p53                      CG           272 (32%)582 (68%)    70 (31%)154 (69%)    26%74%
  PAI                  4 G4 G/5 G       445 (52%)409 (48%)    119 (53%)105 (47%)   50%50%
  TNF                      AG           112 (14%)676 (86%)    28 (12%)206 (88%)    17%83%
  VEGF                     GC           616 (78%)176 (22%)    156 (75%)52 (25%)    80%20%

Gene association studies have identified a number of SNPs (affecting gonadotrophin, steroid and TGFβ pathways, etc.) involved in the ovarian response. Most of them affect mRNA levels or the protein sequence and thus lead to quantitative or functional protein variations that may account for the observed inter-individual variability in the COH. The first SNP to be studied was the FSH receptor polymorphism Asn^680^Ser, which affects baseline FSH level and increases gonadotrophin requirements during COH [@pone.0038700-deCastro1], [@pone.0038700-Behre1]. The ESR1 (−397 T\>C) polymorphism was positively correlated with low oocyte retrieval after COH [@pone.0038700-deCastro2]. AMH (Ile^49^Ser) and AMHR polymorphisms (−482 A\>G) have been associated with variations in oestradiol levels and may modulate FSH sensitivity [@pone.0038700-Kevenaar1]. More recently, it has been suggested that the COH outcome depends on combinations of genetic and environmental factors [@pone.0038700-Altmae1]. In support of this hypothesis, an oligo-SNP model (including FSHR: Asn^680^Ser, ESR1: −397 T\>C, and ESR2:,+1730 A\>G polymorphism) was reportedly associated with a low response to FSH during COH [@pone.0038700-deCastro2]. However, due to the small sample sizes and the heterogeneity of the studied populations, the impact of these polymorphisms requires further investigations.

Here, we sought to evaluate the impact of thirteen polymorphisms (all reportedly associated with variations in IVF results) in a population of women undergoing intracytoplasmic sperm injection (ICSI) program in our center. A multiplex PCR assay was developed and statistical analysis was performed to evaluate the SNPs individual and combined impacts on the COH outcome. We studied the overall study population of patients undergoing ICSI program and selected a subgroup that was homogeneous in terms of patient characteristics.

10.1371/journal.pone.0038700.t002

###### Association of SNPs selected with ovarian response outcome.

![](pone.0038700.t002){#pone-0038700-t002-2}

  Polymorphism    p value   p value after Holm's correction           
  -------------- --------- --------------------------------- -------- --------
  TNF             0.0955                0.9654                0.8595     1
  PAI             0.4745                0.2068                  1        1
  MTHFR2          0.4177                0.3987                  1        1
  HLAG            0.1431                0.7065                  1        1
  BMP15           0.5599                0.0786                  1      0.4680
  ESR1            0.7381                0.6716                  1        1
  AMHR            0.4288                0.1247                  1      0.4070
  MTHFR1          0.1921                0.8440                  1        1
  AMH             0.1268                0.0747                  1      0.6903
  VEGF            0.6470                0.5295                  1        1

10.1371/journal.pone.0038700.t003

###### Multivariate analysis results in both populations.

![](pone.0038700.t003){#pone-0038700-t003-3}

  PopulationGene     Overall studiedn=427   Homogenous n=112
  ----------------- ---------------------- ------------------
  ESR2                      0.0511            Not included
  p53                       0.1685            Not included
  FSHr680                   0.1969               0.0002
  Age                       0.9017               0.3842
  FSH level at J3           0.1409            Not included

Results {#s2}
=======

In the overall study population, we observed a significant difference in the distribution of the oocyte number with age (p\<0.0001) and FSH level (p=0.0044). However, in the homogeneous subgroup, only a slight difference in the distribution of the oocyte number according to age (p=0.0289) was noted.

The allele frequencies in the homogeneous subgroup and in the overall study population are listed in [Table 1](#pone-0038700-t001){ref-type="table"}. The observed frequencies were similar to those quoted on the NCBI website (<http://www.ncbi.nlm.nih.gov/snp>).

After a univariate analysis, only three of the thirteen SNPs (FSHR (p.Asn^680^Ser, +2039 A\>G); p53 (p.Arg^72^Pro, +215 C\>G), and oestradiol receptor 2 (+1730 G\>A) polymorphisms) appeared to be significantly associated with baseline characteristics and/or the number of mature oocytes. These polymorphisms were in Hardy-Weinberg equilibrium, with a 1% error interval.

The other polymorphisms (AMH, AMHR, BMP15, VEGF, MTHFR1, MTHFR2, ESR1, TNFα, HLA-G and PAI) did not appear to influence the number of mature oocytes collected ([Table 2](#pone-0038700-t002){ref-type="table"}).

After applying Holm's correction and a multivariate analysis ([Table 3](#pone-0038700-t003){ref-type="table"}), the influence of p53 (p.Arg^72^Pro) was no longer statistically significant.

In a multilocus analysis of ESR2, p53, FSHR680 and AMH polymorphisms, only the FSHR Asn^680^Ser/AMH Ile^49^Ser combination was found to be associated with the number of mature oocytes after COH.

10.1371/journal.pone.0038700.t004

###### The FSHR (Asn^680^Ser) polymorphism: baseline population characteristics, treatment parameters and ovarian response.

![](pone.0038700.t004){#pone-0038700-t004-4}

  Candidate SNP (rs)             Population              Genotype        Number of women                  Age (years)                           Day-3 FSHlevel (IU/l)                      Day-3 LH level (IU/l)             Amount of exogenous FSH required for ovulationinduction (IU)   Oestradiol level on the day of hCG administration(pg/ml)   Number of mature oocytes
  ----------------------- ------------------------- ------------------- ----------------- ------------------------------------------- ------------------------------------------ ------------------------------------------ -------------------------------------------------------------- ---------------------------------------------------------- --------------------------
  **FSHR** **(rs6166)**    Overall studypopulation        Asn/Asn              142                         30.1±12.6                                   6.6±3.1                                    4.2±2.0                                              2384±947                                                     2197±941                                   7.1±3.9
                                                          Asn/Ser              191         32.0±4.6[a§](#nt102){ref-type="table-fn"}   7.7±4.0[b§](#nt103){ref-type="table-fn"}   4.8±2.4[c§](#nt104){ref-type="table-fn"}                             2386±976                                                     2184±908                                   7.6±3.9
                                                          Ser/Ser              94                          32.0±5.3                                    7.3±2.8                                    4.8±2.2                                              2386±899                                                    2172±1005                                8.1±4.3^d,e,f^
                                                     Asn/Ser + Ser/Ser         285                       32.0±4.8^a\$^                               7.6±3.7^b\$^                               4.8±2.3^c\$^                                           2207±951                                                     2207±951                                   7.7±4.0
                             Homogeneoussubgroup          Asn/Asn              45                          30.3±3.5                                    6.5±1.7                                    4.0±1.5                                              2353±819                                                     2128±802                                   7.2±4.0
                                                          Asn/Ser              46                          30.7±3.7                                    6.0±1.7                                    4.5±2.3                                              2287±748                                                     2245±844                                   8.1±3.3
                                                          Ser/Ser              21                          30.7±3.0                                    6.8±1.5                                    4.2±2.2                                              2278±815                                                     2271±962                                9.8±4.6^g,h,i^
                                                     Asn/Ser + Ser/Ser         67                          30.7±3.5                                    6.3±1.7                                    4.4±2.2                                              2248±764                                                     2253±875                                   8.6±3.8

The major allele was used as a reference.

p value 0.0414 ^a\$^p value=0.0241.

p value=0. 0071, ^b\$^p value=0.0126.

p value c=0.0325, ^c\$^p value=0.0207.

Univariate p value=0.0047, Univariate p after Holm's correction=NS, multivariate p value=NS.

Univariate p value=0.0009, Univariate p after Holm's correction=0.0225, multivariate p value=0.0002.

The FSH Receptor Polymorphism (FSHR p.Asn^680^Ser, +2039 A\>G) ([Table 4](#pone-0038700-t004){ref-type="table"}) {#s2a}
----------------------------------------------------------------------------------------------------------------

In the overall study population, women with the Ser^680^ variant had significantly higher day-3 FSH and LH levels than women who were homozygous for the Asn^680^ variant (7.6±3.7 IU/l vs. 6.6±3.1 UI/l (p=0.0126) for FSH and 4.8±2.3 IU/l vs. 4.2±2.0 IU/l (p=0.0207) for LH, respectively). There was no such association with day-3 FSH or LH levels in the homogeneous subgroup (women under the age of 38 years old and with FSH levels \<10 IU/l). The amount of FSH units administered and the oestradiol level on the day of HCG administration were similar for all genotypes in both the overall study population and the homogeneous subgroup.

![Poor and high response risks, according to FSHR^680^ polymorphism genotypes.](pone.0038700.g001){#pone-0038700-g001}

10.1371/journal.pone.0038700.t005

###### The FSHR (Asn^680^Ser) polymorphism combined with the AMH (Ile^49^ Ser) polymorphism: baseline population characteristics, treatment parameters and ovarian response.

![](pone.0038700.t005){#pone-0038700-t005-5}

  Candidate SNP (rs)          Population             Genotype FSHR (Asn680Ser)/AMH(Ile49 Ser)      Numberof women   Age (years)   Day-3 FSHlevel (IU/ml)   Day-3 LH level(IU/ml)   Amount of exogenous FSH required for ovulationinduction (IU)   Oestradiol level on the day of hCG administration(Pg/ml)           Number of mature oocytes
  -------------------- ------------------------- ------------------------------------------------ ---------------- ------------- ------------------------ ----------------------- -------------------------------------------------------------- ---------------------------------------------------------- ------------------------------------------
  **FSHR/AMH**          Overall studypopulation   Asn^680^/Asn^680^//NNand/or NN/Ile^49^/Ile^49^        314          31.1±9.2            7.3±3.8                  4.7±2.3                                    2395±966                                                     2169±924                                           7.3±3.9
                                                                 Ser^680^/Ser^49^                        14          32.0±3.3            8.6±4.2                  4.7±2.5                                    2443±920                                                     2100±972                           10.3±5.5[a](#nt109){ref-type="table-fn"}
                          Homogeneoussubgroup     Asn^680^/Asn^680^//NNand/or NN/Ile^49^/Ile^49^         82          30.6±3.5            6.4±1.8                  4.4±2.0                                    2367±822                                                     2149±877                                           7.9±3.9
                                                                 Ser^680^/Ser^49^                        5           31.3±1.5            7.7±1.7                  3.2±1.8                                    1770±619                                                     2269±790                           12.8±3.7[b](#nt110){ref-type="table-fn"}

NN: whatever the genotype.

The major allele was used as a reference.

Univariate p value=0.0068.

Univariate p value=0.0090.

Surprisingly, women who were homozygous for the Ser^680^ variant had a greater number of mature oocytes than women who were homozygous for the Asn^680^ variant, with averages of 8.1±4.3 vs. 7.1±3.9 oocytes (p=0.0047) in the overall study population and 9.8±4.6 vs. 7.2±4.0 oocytes (p =0.0009) in the homogeneous subgroup, respectively.

After applying Holm's correction and a multivariate analysis, the FSHR Asn^680^Ser polymorphism was no longer statistically significant in the overall study population. However, it was still significantly correlated (p=0.0225) with the oocyte number in the homogeneous subgroup.

![Poor and high response risks, according to FSHR^680^ and AMH^49^ polymorphism genotypes.](pone.0038700.g002){#pone-0038700-g002}

10.1371/journal.pone.0038700.t006

###### The ESR2 (+1730 G\>A) polymorphism: baseline population characteristics, treatment c parameters and ovarian response.

![](pone.0038700.t006){#pone-0038700-t006-6}

  Candidate SNP (rs)            Population          Genotypes   Women number   Age (years)   Day-3 FSHlevel (IU/ml)            Day-3 LH level(IU/ml)             Amount of exogenous FSH required for ovulationinduction (IU)   Oestradiol level on the day of hCG administration(Pg/ml)          Number of mature oocytes
  ---------------------- ------------------------- ----------- -------------- ------------- ------------------------ ------------------------------------------ -------------------------------------------------------------- ---------------------------------------------------------- -----------------------------------------
  **ESR2 (rs4986938)**    Overall studyPopulation      GG           158         30.9±9.3            7.2±3.7                           4.7±2.3                                              2282±847                                                    2396±1015                                           8.1±4.2
                                                       GA           204         30.8±6.1            7.4±3.3                           4.5±2.1                                              2457±999                                    2067±726[a§](#nt112){ref-type="table-fn"}                       7.2±4.0^b,c,d^
                                                       AA            66         31.1±3.2            7.2±3.9                           4.7±2.3                                             2390±1000                                  2049±915[a\|\|−](#nt113){ref-type="table-fn"}                         7.3±3.6
                                                      AA+AG         270         31.6±7.6            7.4±3.5                           4.6±2.2                                              2440±847                                    2063±872[a\$](#nt114){ref-type="table-fn"}          7.2±3.9[e](#nt116){ref-type="table-fn"}
                            Homogeneoussubgroup        GG            40         30.6±3.2            6.8±1.4                           3.7±1.4                                              2375±752                                                     2299±936                                           7.9±3.6
                                                       GA            56         30.8±3.1            6.3±1.7           4.8±2.3[f§](#nt117){ref-type="table-fn"}                           2145±744^g§^                                                   2238±844                                           8.2±4.4
                                                       AA            16         30.3±3.2            6.4±1.8                           3.7±1.6                           2706±879[g\|\|−](#nt118){ref-type="table-fn"}                                   1849±494                                           8.0±3.1
                                                      AA+AG          72         30.6±3.6            6.4±1.6                         4.6±2.2^f\$^                                           2276±807                                                     2148±791                                           8.1±4.1

The major allele was used as a reference.

p value=0.0016,

p value=0.0155,

p value 0.0007.

Univariate p value=0.0017, Univariate p after Holm's correction=0.0425, multivariate p value=NS.

p value=0.0314.

p value=0.0095, ^f\$^p value=0.0346.

p value AG compared to AA=0.0150.

10.1371/journal.pone.0038700.t007

###### The p53 (Arg^72^Pro) polymorphism: baseline population characteristics, treatment parameters and ovarian response.

![](pone.0038700.t007){#pone-0038700-t007-7}

  Candidate SNP (rs)           Population              Genotype        Women number   Age (years)   Day-3 FSHlevel (IU/ml)   Day-3 LH level(IU/ml)   Amount of exogenous FSH required for ovulationinduction (IU)   Oestradiol level on the day of hCG administration(Pg/ml)          Number of mature oocytes
  --------------------- ------------------------- ------------------- -------------- ------------- ------------------------ ----------------------- -------------------------------------------------------------- ---------------------------------------------------------- -----------------------------------------
  **p53 (rs1045222)**    Overall studypopulation        Arg/Arg            214         31.5±8.0            7.4±3.1                  4.8±2.4                                    2361±978                                                     2162±885                                           7.8±4.3
                                                        Arg/Pro            154         31.6±5.1            7.1±3.5                  4.4±1.9                                    2387±960                                                    2169±1006                                           7.2±3.9
                                                        Pro/Pro             59         30.3±3.9            7.4±4.8                  4.3±2.2                                    2416±781                                                     2322±952                                           7.0±3.3
                                                   Arg/Pro + Pro/Pro       213         31.5±8.0            7.2±3.9                  4.4±2.0                                    2248±997                                                     2401±916                                           7.1±3.7
                           Homogeneoussubgroup          Arg/Arg             60         30.1±3.0            6.6±1.8                  4.4±2.1                                    2175±702                                                     2204±760                                           8.8±3.9
                                                        Arg/Pro             34         31.0±4.1            5.9±1.6                  4.5±1.9                                    2446±862                                                     2132±984                                       7.0±4.1^a,b,c^
                                                        Pro/Pro             16         31.1±3.7            6.3±1.6                  3.3±1.7                                    2476±836                                                     2335±862                                           7.7±3.0
                                                   Arg/Pro + Pro/Pro        50         31.1±3.9            6.1±1.6                  4.1±1.9                                    2198±942                                                     2457±845                           7.2±3.8[d](#nt121){ref-type="table-fn"}

The major allele was used as a reference.

Univariate p value=0.0048, Univariate p after Holm's correction=NS, multivariate p value=NS.

p value=0.0451.

Moreover, in the overall study population, we observed that women who were homozygous for the Ser^680^ variant were less likely to have had a low response than women who were homozygous for Asn^680^ (18% vs. 27%, respectively). Likewise, women who were homozygous for the Ser^680^ variant were more likely to have had a high response than women who were homozygous for Asn^680^ (24% vs. 12%, respectively) (p=0.0131). These observations were also confirmed in the homogeneous subgroup (p=0.046) ([Figure 1](#pone-0038700-g001){ref-type="fig"}).

The Combination of FSHR and AMH Polymorphisms ([Table 5](#pone-0038700-t005){ref-type="table"}) {#s2b}
-----------------------------------------------------------------------------------------------

Within both the overall study population and the homogeneous subgroup, the AMH Ile^49^ Ser polymorphism was not associated with any clinical or hormonal parameters or the number of oocytes retrieved. However, in both populations, women who were homozygous for both the FSHR Ser^680^ variant and AMH Ser^49^ variant yielded more mature oocytes than women who were homozygous for FSHR Asn^680^ and/or homozygous for AMH Ile^49^ with 10.3±5.5 and 7.3±3.9 mature oocytes (p=0.0068) in overall study population and 12.8±3.7 vs. 7.9±3.9 mature oocytes (p=0.009) in the homogenous subgroup.

In the overall study population, we observed that women who were homozygous for the FSHR Ser^680^ and AMH Ser^49^ variants were less likely to have had a low response than women who were homozygous for FSHR Asn^680^ and/or homozygous for AMH Ile^49^ (14% vs. 24%, respectively). Similarly, women who were homozygous for the FSHR Ser^680^ and AMH Ser^49^ variants were more likely to have a high response than women who were homozygous for FSHR Asn^680^ and/or homozygous for AMH Ile^49^ (43% vs. 14%, respectively) (p=0.0188). These observations were confirmed in the homogeneous subgroup (p=0.004) ([Figure 2](#pone-0038700-g002){ref-type="fig"}).

The Oestradiol Receptor 2 Polymorphism (ESR2+1730 G\>A) ([Table 6](#pone-0038700-t006){ref-type="table"}) {#s2c}
---------------------------------------------------------------------------------------------------------

In the overall study population, there was no association between this polymorphism and the day-3 serum levels of LH and FSH. However, in the homogeneous subgroup, an elevated LH serum level was observed for heterozygous women, with mean LH levels of 3.7±1.4, 4.8±2.3 and 3.7±1.6 IU/l for the GG, GA and AA genotypes, respectively. Day-3 E2 and FSH levels did not vary with genotype in the homogeneous subgroup.

The amount of FSH administered was not associated with the polymorphism in the overall study population. However, the mean E2 level on the day of hCG administration was higher in women who were homozygous for the G allele (2396±1015 pg/ml) than in heterozygous women and women who were homozygous for the A allele (2067±726, p=0.0016 and 2049±915 pg/ml, p=0.0155 respectively).

In the overall study population, women who were homozygous for the G allele had a greater mean number of mature oocytes than (i) women who were heterozygous for the A allele (8.1±4.2 vs. 7.2±4.0, respectively; p=0.0017) or (ii) group of women who were homozygous or heterozygous for the A allele (8.1±4.2 vs. 7.2±3.9, respectively; p =0.0314).

The results differed in the homogeneous subgroup, where the number of mature oocytes was not associated with the polymorphism. However, women who were homozygous for the A allele required more exogenous FSH (2706±879 IU) than women who were homozygous or heterozygous for the G allele (2375±752 IU and 2145±744 IU respectively) to produce a similar number of oocytes.

In the overall study population, the ESR2 polymorphism was still significantly correlated with the oocyte number after applying Holm's correction (p=0.0425) but not after a multivariate analysis (p=0.0511). In both populations, there were no relationships between this polymorphism and the likelihood of a low or high response.

The p53 Gene Polymorphism (p.Arg^72^Pro, +215 C\>G) ([Table 7](#pone-0038700-t007){ref-type="table"}) {#s2d}
-----------------------------------------------------------------------------------------------------

In both populations, there were no genotype-related differences in terms of age, day-3 hormone levels, the amount of FSH required for ovulation induction and the E2 level on the day of HCG administration.

In the overall study population, the number of mature oocytes obtained was not significantly associated with the genotype).

In the homogeneous subgroup, women who were homozygous for the Arg^72^ variant had a greater number of oocytes than (i) women who were heterozygous for the Pro^72^ variant (8.8±3.9 vs. 7.0±3.3, respectively; p=0.0048) and (ii) group of women who were homozygous and heterozygous for Pro^72^ variant (8.8±3.9 vs. 7.2±3.3, respectively; p =0.0451). However, this difference was no longer significant after applying Holm's correction and a multivariate analysis.

Moreover, in the homogenous subgroup, we observed that women who were homozygous for Arg^72^ were less likely to have a low response than women who were heterozygous or homozygous for the Pro^72^ allele (15% vs. 28%, respectively). Accordingly, the women who were homozygous for Arg^72^ were more likely to show a high response than those who were heterozygous or homozygous for Pro^72^ allele (23% vs. 12%, respectively; p=0.0429) ([Figure 3](#pone-0038700-g003){ref-type="fig"}).

![Poor and high response risks, according to p53^72^ polymorphism genotypes.](pone.0038700.g003){#pone-0038700-g003}

10.1371/journal.pone.0038700.t008

###### Women characteristics.

![](pone.0038700.t008){#pone-0038700-t008-8}

  Women characteristics    Overall study population    Homogeneous subgroup  
  ----------------------- --------------------------- ---------------------- -------------
  Patients number (n=)                427                      112           
  Age (years)                      31,2±9.55                30.6±3.53        
  **Hormonal profile**     **Day-3 E2 level(IU/ml)**       46.27±26.15        46.89±28.17
                            Day-3 LH level (IU/ml)          4.64±2.77          4.32±2.02
                            Day-3 FSH level (IU/ml)         7.02±2.44          6.40±1.74
  ICSI indication                 IVF failure                 28.6%               0%
                               Male infertility               71.4%              100%
  Menstruel cycle                   Normal                    77.6%              100%
                                   Abnormal                   22.4%               0%
  Ovulation                         Normal                    21.7%              100%
                                   Abnormal                   78.3%               0%
  Ethnic origin                    Caucasian                   80%               100%
                                    Others                     20%                0%

Discussion {#s3}
==========

Of the thirteen polymorphisms studied here, only three SNPs (in the genes coding for FSHR, ESR2 and p53) and one SNP combination (FSHR Asn^680^Ser/AMH Ile^49^Ser) appeared to be significantly associated with the number of mature oocytes retrieved after COH. To improve our analysis, we applied Holm's correction for p-values and performed a multivariate analysis to evaluate the polymorphisms' respective impacts on the women's IVF results.

The polymorphisms studied here have been previously shown to affect the response in some but not all studies.

We did not genotype FSHr307 in the current study because it is in near-complete linkage disequilibrium with FSHr680 [@pone.0038700-Simoni1]. In the present study, we investigated gene-environment interactions. Both genetic variants and environmental factors (as age, ovulation and length of cycle) have a significant influence on the ovarian response to gonadotrophins.

We showed that some effects are not apparent in the unselected ICSI population and clearly highlights the care that must be taken when comparing these studies. For example, FSH and LH levels on day 3 were not dependant on the FSH receptor polymorphism but a difference was found in the total unselected ICSI population. Thus, differences between studies might reflect the heterogeneity of included patients. In the homogeneous subgroup, the woman's age and FSH level had less impact on the number of oocytes retrieved and so clearer conclusion could be drawn in this respect - even though the sample size was very small.

The FSH Receptor Polymorphism (FSHR p.Asn^680^Ser, FSHR 2039 A\>G) {#s3a}
------------------------------------------------------------------

In the homogeneous subgroup, there was no relationship between the genotype on one hand and the day-3 FSH level or age on the other - mainly because an FSH level below to 10 IU/l and age under 38 were criteria for inclusion in this subgroup.

In contrast, in the overall study population, we found that a significantly higher day-3 serum FSH level was associated with the FSHR Ser^680^ variant. The increased age might explain the increased day 3 FSH. These data indicate that the polymorphism has no effect on young patients but might interfere when the patients are getting older.

The genotype did not appear to be associated with the amount of exogenous FSH. The attending gynaecologists were blinded to the genotype at the time of prescription. Similarly, there was no FSHR genotype-related difference in the E2 level on the day of hCG administration.

As described in the Results section, the women who were homozygous for the FSHR Ser^680^ variant were less likely to have been low responders and more likely to have been high responders. These results were confirmed in the overall study population. Furthermore, the statistical significance after Holm's correction and a multivariate analysis confirmed the impact of the FSHr680 genotype on the ovarian response to rFSH in IVF cycles.

Several previous studies have sought a correlation between the FSHR polymorphism and the outcome of the ovarian response but yielded discordant results.

In contrast with our present results, it has been reported that FSHR Asn^680^Ser is associated with a low E2 level during ovarian stimulation. To achieve similar oestradiol peak levels, homozygous FSHR Ser^680^ women were found to need more exogenous FSH than women with FSHR Asn^680^ [@pone.0038700-deCastro1], [@pone.0038700-Behre1], [@pone.0038700-PerezMayorga1]. Indeed, other researchers have suggested that women with the FSHR Ser^680^ polymorphism have a higher ovarian threshold for FSH and thus a longer follicular cycle. The FSHR Ser^680^ polymorphism has also been linked to lower sensitivity to the action of FSH [@pone.0038700-Greb1].

Other studies have not found any association between FSHR Ser^680^ polymorphism and various baseline hormone levels or the amount of exogenous FSH required for ovarian stimulation [@pone.0038700-Sudo1]--[@pone.0038700-Achrekar1]. More recently, it was reported that women who were homozygous for the FSHR Asn^680^ polymorphism needed higher amounts of exogenous FSH and tended to need more stimulation days [@pone.0038700-Anagnostou1]. This observation is concordant with our present study, in which women who were homozygous for FSHR Asn^680^ had fewer mature oocytes than women homozygous for FSHR Ser^680^ (despite the administration of similar amounts of exogenous FSH).

In other studies, women who were homozygous for the FSHR Ser^680^ polymorphism were more at risk of a high response and iatrogenic OHSS after similar ovarian stimulation [@pone.0038700-Achrekar1], [@pone.0038700-Daelemans1]. Only the occurrence of moderately intense OHSS was correlated with the FSHR Ser ^680^ polymorphism [@pone.0038700-Daelemans1]. Our results were similar, with an increased likelihood of a high response (≥12 mature oocytes) for women who were homozygous for the FSHR Ser^680^ polymorphism. The occurrence of iatrogenic hyperstimulation is probably linked to the hypersensitivity to FSH; this is quite unexpected because the Ser^680^ polymorphism has previously been correlated with low sensitivity to FSH [@pone.0038700-deCastro1].

There is currently no evidence of an effect of the FSHR genotype on hormone binding characteristics or cAMP or inositol phosphate production following FSH stimulation. It is also possible that the FSHR Asn^680^Ser polymorphism only has a direct impact on the ovarian gonadotrophin response and oocyte recruitment when it is combined with other polymorphisms.

This hypothesis was strengthened by the results of our study, since the association between the FSHR polymorphism and the number of mature oocytes appeared to be higher when combined with the AMH Ile^49^Ser polymorphism (which is thought to slightly alter the biological activity of AMH [@pone.0038700-Kevenaar2]).

In both the overall study population and the homogeneous subgroup, the AMH Ile^49^Ser polymorphism alone was not significantly associated with baseline day-3 hormone levels or the number of mature oocytes recovered after COH. Our results agree with previous data in this respect (Hanevik et al. 2010).

In both the overall study population and the homogeneous subgroup, we found that women who were homozygous for both the FSHR Ser^680^ and the AMH Ser^49^ alleles had a significantly greater mean number of mature oocyte numbers than women who were homozygous for FSHR Asn^680^ and/or homozygous for AMH Ile^49^-- even though the various groups received similar amounts of exogenous FSH. A genotype-related difference was also present in the overall study population and the homogeneous subgroup when we compared the likelihood of belonging to the subgroups formed according to the number of oocytes. An increased likelihood of a high response was observed for women who were homozygous for both the FSHR Ser^680^ and the AMH Ser^49^ alleles, when compared with women who were homozygous for FSHR Asn^680^ and/or homozygous for AMH Ile^49^.

It has been shown that AMH-knockout mice display fast, high-quality primordial follicle recruitment and have a more pronounced response than the wild type in the presence of high serum FSH concentrations. In view of these data, AMH inhibits primordial follicle growth *in vitro* [@pone.0038700-Durlinger1]--[@pone.0038700-Carlsson1] and attenuates sensitivity to FSH. Conversely, follicles are more responsive to FSH in the absence of AMH [@pone.0038700-Durlinger2], [@pone.0038700-Visser1].

These data are in agreement with our results, which suggest that AMH and FSH polymorphisms might improve the recruitment of primordial follicles. Our findings also suggest that the combination of AMH and FSHR polymorphisms may have potential value as a marker for the ovarian response in women undergoing IVF treatment but due to sample size this finding needs to be confirmed.

10.1371/journal.pone.0038700.t009

###### Gene polymorphisms reportedly involved in IVF outcomes.

![](pone.0038700.t009){#pone-0038700-t009-9}

  Gene name                      Protein name                             Protein function                     Variant Name                                                                                     Association with ovarian response                                                                               Association with embryo implantation                                                    
  -------------- -------------------------------------------- ---------------------------------------- ---------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ -------------------------------------- ------------------------------------------------- -----------------------------
  ***AMH***                 Anti-Mullerian hormone                            Hormone                    +146 G/T (p.Ile^49^Ser)                                                                       [@pone.0038700-Kevenaar1], [@pone.0038700-Kevenaar2]                                                                           [@pone.0038700-Hanevik1]                                                          
  ***AMHR2***       Anti-Mullerian hormone type IIreceptor                Hormone receptor                      --482 A/G                                                                              [@pone.0038700-Kevenaar1], [@pone.0038700-Kevenaar2]                                                                           [@pone.0038700-Hanevik1]                                                          
  ***BMP15***            Bone morphogenic protein 15              Oocyte and follicle development                 −9 C/G                                                                                              [@pone.0038700-Moron1]                                                                                                                                                                            
  ***ESR1***                 Oestrogen receptor 1                         Hormone receptor                       −397 T/C                                                                [@pone.0038700-deCastro2], [@pone.0038700-Altmae2], [@pone.0038700-Sundarrajan2]                                                                                                                                               
  ***ESR2***                 Oestrogen receptor 2                         Hormone receptor                      +1730 A/G                                                 [@pone.0038700-deCastro2], [@pone.0038700-Sundarrajan1], [@pone.0038700-Altmae2], [@pone.0038700-Sundarrajan2]                                                                                                                                
  ***FSHR***         Follicle-stimulating hormonereceptor                 Hormone receptor              +2039 A\>G (p.Asn^680^Ser)   [@pone.0038700-deCastro1]--[@pone.0038700-deCastro2], [@pone.0038700-PerezMayorga1]--[@pone.0038700-Achrekar1], [@pone.0038700-Daelemans1], [@pone.0038700-Jun1]--[@pone.0038700-Greb2];        [@pone.0038700-Klinkert1]         [@pone.0038700-Jun1], [@pone.0038700-Klinkert1]  
  ***HLA-G***     Major histocompatibilitycomplex class I, G    Antigen processing and presentation             --725 C/G                                                                                                                                                                                                                                                         [@pone.0038700-Roussev1]              
  ***MTHFR1***        Methylenetetrahydrofolatereductase                 Folate metabolism               +677 C/T (p.Ala^222^Val)                                                                                    [@pone.0038700-Thaler1]                                                                                           [@pone.0038700-Rosen1]                       [@pone.0038700-Azem1]                [@pone.0038700-Martinelli1]
  ***MTHFR2***        Methylenetetrahydrofolatereductase                 Folate metabolism              +1298 A/C (p.Glu^429^Ala)                                                                                     [@pone.0038700-Rosen1]                                                                                                                                      [@pone.0038700-Haggarty1]             
  ***P 53***                  Tumour protein p53                    Apoptosis and DNA reparation         +215 C/G (p.Arg^72^Pro)                                                                                      [@pone.0038700-Kang1]                                                                                                                                         [@pone.0038700-Kay1]                
  ***PAI-1***          Plasminogen activatorinhibitor-1          Tissue development and coagulation           −675 (4 G/5 G)                                                                                                                                                                                                                                                       [@pone.0038700-Coulam1]              
  ***TNF***              Tumour necrosis factor alpha                Pro-inflammatory cytokine                   −308 A/G                                                                                                                                                                                                                                                         [@pone.0038700-Vialard1]              
  ***VEGF***          Vascular endothelial growthfactor        Vascular permeability and angiogenesis            +405 G/C                                                                                                                                                                                                                                                         [@pone.0038700-Goodman1]              

The Oestrogen Receptor β Gene Polymorphism (ESR2+1730 G\>A) {#s3b}
-----------------------------------------------------------

In the overall study population, women who were heterozygous or homozygous for the A allele had a significantly greater number of mature oocytes than those who were homozygous for the G allele, despite receiving similar amounts of exogenous FSH. Statistical impact of ESR2+1730 genotype on ovarian response to rFSH in IVF cycle was confirmed using Holm's correction but not using multivariate analysis. This discrepancy is probably due to sample size, limited for multivariate analysis.

No difference was observed in the homogeneous subgroup; women who were homozygous for the A allele needed to receive more exogenous FSH than women who were heterozygous for the A allele (2706±879 IU and 2145±744 IU, respectively; p=0.0150) to achieve adequate oocyte maturation and obtain a similar number of oocytes. Heterozygous women received similar amounts of exogenous FSH when compared with women who were homozygous for the G allele but had a higher day-3 LH level; which may contribute to best final adequate oocytes maturation. There were no genotype-related differences in the likelihood of belonging to the low-response or high-response groups.

In view of previous reports [@pone.0038700-Sundarrajan1] associating ESR2 polymorphism with ovulatory dysfunction, we believe that our fertility-based inclusion criteria for the homogeneous subgroup (i.e. excluding women with known causes of infertility) can explain why the ESR2 polymorphism was not associated with the nature of the ovarian response.

Although oestrogen's action is mediated by the ESR1 and ESR2 receptors, the latter predominates in the ovary [@pone.0038700-Byers1], [@pone.0038700-Drummond1]. ESR2 stimulates early folliculogenesis, decreases follicular atresia and stimulates late follicular growth [@pone.0038700-HegeleHartung1] by inducing the action of FSH. In turn, FSH promotes granulosa cell proliferation. ESR2 action may thus explain the synergistic effect of oestrogen and FSH on the number of FSH receptors in granulosa cells (resulting in follicular growth and maturation [@pone.0038700-Ireland1]). However, our data did not reveal an association between the FSHR p.Asn^680^Ser and ESR2+1730 G\>A polymorphisms on ovarian response.

ESR2 knockout mice have inefficient ovulation efficiency and produce few oocytes. This is mainly due to a defect within ovarian tissue in general [@pone.0038700-Windahl1], [@pone.0038700-Krege1] and inability of E2 to exert its effect on the granulosa cells in maturing follicles in particular. Furthermore, it has been shown that ESR2 had no effect on the serum concentration of pituitary reproductive hormones [@pone.0038700-Scully1]. Our results are in agreement with ESR2-knockout mouse data, since the mRNA of the ESR2+1730 A variant folds differently and is expressed less [@pone.0038700-Putnik1]. Furthermore, it has also been shown that follicles with low oestrogen level had low-quality, apoptotic oocytes [@pone.0038700-Fishel1], [@pone.0038700-BoteroRuiz1], which could reduce the number of mature oocytes.

Hence, our results suggest that the ESR2+1730 G\>A polymorphism modulates the IVF outcome by affecting the number of mature oocytes.

10.1371/journal.pone.0038700.t010

###### Primer design for the selected SNPs.

![](pone.0038700.t010){#pone-0038700-t010-10}

  Gene name    Referencesequence   Primer (5′-3′)                                   PCR product size                                            
  ----------- ------------------- ---------------- ---------------------------------------------------------------------------------- --------- --------
  AMH             rs10407022          F1 F2 R             CACAGAGGCTCTTGTGGG**C** CACAGAGGCTCTTGTGGG**A** GATAGGGGTCTGTCCTGCAC         FAM HEX    247
  AMHR             rs2002555          F1 F2 R              CCTTCCTCTGCCCAAGC**A** CCTTCCTCTGCCCAAGC**G** CCAGCTGAGAACCCAGTGAT          FAM HEX    207
  BMP15            rs3810682          F1 F2 R           GAGGAGGACCATCTTGAAAG**G** GAGGAGGACCATCTTGAAAG**C** ATGAGGCAACTTTGGTCCAG       FAM HEX    197
  ESR1             rs2234693          F1 F2 R           GAGTTCCAAATGTCCCAGC**T** GAGTTCCAAATGTCCCAGC**C** GGGGAAATTGTTTATTGCAAAC       FAM HEX    234
  ESR2             rs4986938          F1 F2 R              GGCCCACAGAGGTCACA**G** GGCCCACAGAGGTCACA**A** CTTCCTCACACCGACTCCTG          FAM HEX    157
  FSHR              rs6166            F1 F2 R         GACAAGTATGTAAGTGGAACCA**T** GACAAGTATGTAAGTGGAACCA**C** TGTTTCACCCCATCAACTC      HEX FAM    224
  HLA-G                               F1 F2 R       TGAAACTTAAGAGCTTTGTGAGTC**C** TGAAACTTAAGAGCTTTGTGAGTC**G** AGTTGTGCCTGAGTGCATGA   FAM HEX    191
  MTHFR1           rs1801133          F1 F2 R              GAAGGTGTCTGCGGGAG**C** GAAGGTGTCTGCGGGAG**T** AGAACTCAGCGAACTCAGCA          FAM HEX    238
  MTHFR2           rs1801131          F1 F2 R            GAGGAGCTGACCAGTGAAG**C** GAGGAGCTGACCAGTGAAG**A** ACAGGATGGGGAAGTCACAG        HEX FAM    178
  p53             rs10425222          F1 F2 R                 CAGAGGCTGCTCCC**C** CAGAGGCTGCTCCC**G** GACTTGGCTGTCCCAGAATG             FAM HEX    163
  PAI              rs1799889          F1 F2 R           TCA**GGGG**CACAGAGAGAGTC TCA**GGGGG**CACAGAGAGAGTC CAGCCACGTGATTGTCTAGG        FAM HEX   148149
  TNF              rs1800629          F1 F2 R            ATAGGTTTTGAGGGGCATG**A** ATAGGTTTTGAGGGGCATG**G** GAGTCTCCGGGTCAGAATGA        FAM HEX    184
  VEGF             rs2010963          F1 F2 R                CTCACTTTGCCCCTGTC**G** CTCACTTTGCCCCTGTC**C** GAGGCGCAGCGGTTAG            HEX FAM    351

The p53 Gene Polymorphism (p. Arg^72^Pro, +215 G\>C) {#s3c}
----------------------------------------------------

In the overall study population and in the homogeneous subgroup, the FSH treatment did not vary as a function of the p53 polymorphism. However, for the homogeneous subgroup, we observed that women who were homozygous for the Arg^72^ allele had a significantly higher mean number of retrieved oocytes than women who were heterozygous or homozygous for the Pro^72^ polymorphism. As this result was no longer statistically significant after Holm's correction and a multivariate analysis, these data should be considered with a degree of caution. Further analyses are required to confirm or repudiate this finding.

Moreover, the genotype p53 Arg^72^ appeared to increase the likelihood of a high response and decrease the likelihood of a low response in the homogeneous subgroup.

The p53 tumour suppressor protein plays a crucial role in maintaining genomic stability in somatic cells. It has been shown that small changes in the level and/or activity of p53 can alter its functional efficiency. In *Drosophila* and *C. elegans*, p53 protein is most commonly expressed in germ cells, where it eliminates defective gametes and, consequently, defective offspring from the population [@pone.0038700-Ollmann1], [@pone.0038700-Derry1].

The first report of an impact of p53 on fertility found a high association between the Pro^72^ polymorphism and recurrent implantation failure [@pone.0038700-Kay1]. It has been further suggested that p53 regulates female reproduction and blastocyst implantation through transcriptional up-regulation of uterine leukocyte inhibitory factor (LIF), which is an important factor in implantation. Elevated endometrial LIF levels are observed at the time of implantation in fertile women [@pone.0038700-Aghajanova1]. Women with unexplained infertility have lower LIF levels than fertile women do [@pone.0038700-Laird1], [@pone.0038700-Mikolajczyk1].

In agreement with our present results, it has been reported that the Pro^72^ polymorphism is highly associated with decreased pregnancy rates after fresh IVF, via an ovarian mechanism [@pone.0038700-Kang1]. Even though functional impact of p53 on oogenesis has not yet been investigated, one can hypothesize that low p53 activity is associated with greater DNA damage during folliculogenesis and oogenesis. Although genetic predispositions must always be confirmed in larger series, the p53 Arg^72^Pro polymorphism appears to have a significant impact on the ovarian response in women undergoing IVF treatment.

In conclusion, our objective was to determine a genetic profile suitable for use prior to the IVF protocol, in order to adjust the amount of prescribed FSH. We genotyped women after participation in an IVF protocol and investigated the potential usefulness of genetic testing for predicting the COH response. On the basis of literature reports, we identified thirteen polymorphisms that may impact ovarian function. Using a univariate statistical analysis, we found that three of the latter polymorphisms (in the genes coding for the FSHR, ESR2 and p53) and one combination of polymorphisms (FSHr680/AMH) were significantly associated with the number of mature oocytes retrieved after COH. After Holm's correction and a multivariate analysis, p53 was no longer statistically significant.

There is a need for clinical studies in which the amount of FSH given to patients is modulated according to the genotype - especially for women who are genetically predisposed to low or high responses to COH.

![Electrophoregram profile with the 13 polymorphisms genotyped.\
The first and second lines show alleles fluorescently tagged with FAM and Hex dyes, respectively. The last electropherogram is the RO×500 size standard.](pone.0038700.g004){#pone-0038700-g004}

Materials and Methods {#s4}
=====================

Subject Population {#s4a}
------------------

The study was approved by an independent ethics committee (the *Comité Consultatif de Protection des Personnes dans la Recherche Biomédicale*; project reference: 01032) and was performed in accordance with the tenets of the Declaration of Helsinki. All the women provided their prior, written, informed consent to participation.

We included a total of 427 women undergoing an initial ICSI procedure with oocyte retrieval and embryo transfer for severe male infertility. Before the ICSI procedure, the patients had been extensive evaluated in terms of their personal and family medical history, clinical and serological status, hysterosalpingography, day-three hormonal profile (FSH, luteinizing hormone and estrogen) and karyotype. The exclusion criteria included, prior chemotherapy, unilateral ovariectomy, maternal diethylstilbene treatment, an abnormal karyotype or any identified genetic abnormalities.

To lessen the impact of age and FSH level on our results, we then selected a Caucasian subgroup (n=112) that was homogeneous in terms of age and the absence of known aetiological factors for female infertility. The criteria for this subgroup were as follows: Caucasian origin, normal karyotype, age under 38, a day-three serum FSH level below 10 IU/l and the combination of a long GnRH agonist desensitization protocol and treatment with recombinant FSH for COH. The exclusion criteria included uterine malformation, grade 3 or 4 endometriosis, polycystic ovary syndrome (PCOS). Clinical and demographic characteristics were described in [Table 8](#pone-0038700-t008){ref-type="table"}.

Ovarian follicle stimulation was performed with recombinant FSH (GonalF® from Merck Serono or Puregon® from Organon-Schering Plough) and monitored by estrogen measurements and transvaginal ultrasound from day 5 onwards. Ovulation was induced with 10,000 IU of hCG or recombinant hCG. Transvaginal, ultrasound-guided follicle aspiration was performed 35 hours later and maturity of oocytes with a single polar body was evaluated after hyaluronidase treatment.

The number of mature oocytes obtained after ovarian hyperstimulation was analysed by genotype. In order to evaluate the association between the SNPs and the average number of oocytes in response to COH, we divided the population into three categories: low responders (4 oocytes or less), normal responders (between 5 and 11 oocytes) and high responders (12 oocytes or more).

DNA Preparation {#s4b}
---------------

For each patient, a blood sample was collected for DNA analysis. Genomic DNA was extracted using the Wizard® Genomic DNA Purification Kit (Promega, Southampton, UK), according to the manufacturer's protocol. Genotyping was performed after the IVF procedures had been completed.

SNPs Selected for Genotyping {#s4c}
----------------------------

We selected thirteen SNPs that reportedly impact the ovarian response and/or embryo implantation in women in IVF programmes ([Table 9](#pone-0038700-t009){ref-type="table"}):

Primer Design {#s4d}
-------------

For each of these thirteen selected SNPs, an allele-specific PCR assay was developed. Primer pairs were designed using Primer3 online software ([www.ncbi.nlm](http://www.ncbi.nlm)) ([Table 10](#pone-0038700-t010){ref-type="table"}). Each primer set was carefully designed for compatibility with a multiplex PCR assay, with a (i) products between 150--350 base pairs that can be identified on capillary electrophoresis and (ii) a melting temperature (T~m~) close to 60±2°C. Each allele-specific forward or reverse primer was marked with either 6-carboxyfluorescein (FAM, blue colour) or hexachlorocarboxyfluorescein (HEX, green colour) and synthesized by Eurogentec (Serain, Liege, Belgium). After receipt, primers were diluted to an appropriate concentration for PCR assays in 10 mM Tris buffer and stored at −20°C until use.

Allele-specific PCR Validation {#s4e}
------------------------------

The 20 µl PCR reaction mixture (QIAGEN Hilden, Germany) contained 2 µl of extracted DNA, 0.2 µM of each primer. A Silver 96-Well GeneAmp 2700 PCR System was used for DNA amplification. A denaturation step was first performed (15 min at 95°C) followed by 24 PCR cycles (denaturation: 30 seconds at 94°C; annealing: 90 seconds at 65°C; extension: 60 seconds at 72°C) and a final extension phase (30 min at 60°C). All experiments were repeated twice.

Multiplex PCR Conditions {#s4f}
------------------------

Multiplex PCR was carried out in 20 µl reaction volumes, containing 2 µl of extracted DNA containing 0.2 µM of all primers Thermal cycling was performed using the conditions described above. All experiments were also repeated twice.

Genotyping {#s4g}
----------

PCR products were diluted 1∶10 in sterile water, and 1 µL of this dilution was added to 20 µL of a mixture containing 19.5 µL Formamide® (Applied Biosystems, Foster City, California, USA) and 0.5 µl RO×500 size standard (Applied Biosystems) in 96-well PCR plates. The samples were denatured for 3 min at 95°C.

Multiplex PCR products were separated by capillary electrophoresis using an ABI Prism 3100 genetic analyzer (Applied Biosystems). Allelic call was performed using the Genemapper® ID v.3.1 software (Applied Biosystem) ([Figure 4](#pone-0038700-g004){ref-type="fig"}).

Statistics {#s4h}
----------

Statistical analysis was performed in three steps:

### 1. Univariate analysis {#s4h1}

For age, the day-3 serum levels of LH and FSH, the amounts of exogenous FSH and the oestradiol level on the day of hCG administration, means were compared in an analysis of variance. The threshold for statistical significance was set to 5%.

For the oocyte number, the means were compared using generalized linear models (GLMs) supported by the GENMOD procedure (SAS Institute Inc., Cary, NC, USA), with the hypothesis of a Poisson distribution for the response variable.

For each genotype, the respective proportions with a high response (≥12 mature oocytes) and a low response (≤4 mature oocytes) were compared in a Stat view program (SAS institute) using Chi-2 and Fisher tests.

To take into account multiple testing for the polymorphisms, the familywise error rate was adjusted with the sequential Bonferroni-Holm procedure [@pone.0038700-Holm1]. Deviations from the Hardy-Weinberg equilibrium were assessed by means of a Chi-2 test.

### 2. Multivariate analysis {#s4h2}

We performed a multivariate analysis with all polymorphisms and putative confounding clinical factors (age, FSH level, cycle length and ease of ovulation). All polymorphisms found to be significant at p≤0.30 after Holm's correction were introduced as covariates into GLM models. Any suitable, first-order interactions derived from these factors were also added as covariates. Final models were obtained using backward selection of variables, with the likelihood ratio as the selection criterion. Variables with p\>0.05 and \<0.10 were kept in the final models.

### 3. Multilocus analysis {#s4h3}

Lastly, in order to better identify polymorphism interactions, a multilocus analysis was performed with GLM models. All polymorphisms found to be significant at p≤0.075 in the univariate analysis (without Holm correction) were introduced into the multilocus analysis; this enabled us to decrease the number of independent covariates in the models. Backward selection of variables was performed as above, and variables with p\>0.05 and \<0.10 were kept in the final models.
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